Agile Devices is commercializing a novel coaxial deflection microcatheter.  We have developed the Angler™ as a first product, targeting vascular interventional use of microcatheters, which is a $300-400 million global market.

Our patented technology was designed to improve maneuverability with an actively controlled deflectable tip which can enable faster vessel navigation.  Key anticipated benefits include reduced procedure times and cost, increased operating room availability, and improved patient outcomes.

We believe that several other segments within the very large overall global catheter market are also highly addressable by our novel patented coaxial deflection technology.

カテーテル先端を曲げ向きや角度を変えることができる同軸技術を開発。Anglerで5億ドルの市場規模をもつ血管用マイクロカテーテル市場参入を狙う。これによりカテーテル挿入が迅速になるとともに、ガイドワイヤ―やカテーテル交換を削減することができる。300億ドル（2019年）と言われる世界のカテーテル市場の一部をこの同軸技術で対応可能。

___

Stephen Tully, Vice President of R&D and Technical Operations

I have over 25 years of device design R&D and program management experience in the medical device field with both very large and startup companies.

I started my engineering career at USCI / Bard Cardiology developing guidewires, diagnostic and guide catheters, introducers and rapid exchange dilatation catheters.  I then worked for Covidien managing in their Urology R&D group and then at Terumo managing their Glidesheath® introducer kit R&D group.

Most recently before joining Agile, I worked at a startup company called Beacon Endoscopic developing rapid exchange EUS Fine Needle Aspiration devices.  Beacon was acquired by Covidien where I continued to commercialize line extensions for our technology.

Centerline Biomedical is a Cleveland Clinic spinoff company commercializing the Intra-Operative Positioning System (IOPS™) technology — an innovative, non-x-ray based 3D GPS-like surgical navigation technology that improves endovascular procedure outcomes and reduces radiation exposure.

The goal to create the first and only 3D visualization and real-time navigation system that allows physicians to perform optimal, radiation-free image-guided endovascular surgery developed when Vikash Goel, current Chief Technology Officer at Centerline Biomedical set out to fulfill his mentor Dr. Roy K. Greenberg’s vision of advancing endovascular surgery. After years of hard work and dedication by vascular physicians and researchers at the Cleveland Clinic, IOPS was born, with a working prototype and first-in-man data.

Centerline Biomedicalは周術期位置情報システム（IOPS）を商用化すべくクリーブランド・クリニックからスピンオフした会社です。IOPSは、X線を使わずに3次元的に手術を可視化しナビゲーションをする技術で、血管手術の成功率を上げ放射線使用量を減らすことができます。

クリーブランドクリニックにおける血管系医師や研究者達の長年の努力の結果、IOPSが生まれ、既にプロトタイプが作成されて、ヒトに適用されデータ収集が始まっています。

___

Philip D. Rackliffe, Chief Executive Office (CEO)

With 25 years of experience in healthcare executive management and business development, Mr. Rackliffe has successfully led start-ups, managed company divisions exceeding $2B in annual revenue, and launched 25+ global products across both the public and private sectors of the medical device and pharmaceutical industries. He has held global executive leadership positions spanning CEO, GM, Global Franchise Head, Marketing, Sales, Operations, Strategy, Business Development and Process Improvement. Currently serving as CEO of Centerline Biomedical, he has successfully closed over $15M in capital and built a world class management team.

Centese is a start-up Medical Device company modernizing the field of post-operative drainage following cardiac and thoracic surgery. Centese has developed Thoraguard, the most advanced technology available to replace the analog standard of care systems in use at nearly every cardiothoracic surgery center in the world. Using proprietary design, integrated sensors for data collection, and intelligent software control Thoraguard improves post-operative care following these life-saving procedures. Thoraguard has been clinically validated by word-class cardiothoracic centers Stanford University and NYU-Langone Medical Center and is preparing for commercialization.

Centeseが開発したThoraguard™は、インテリジェントセンサーとソフトウエアを活用したデジタルドレナージシステムで、手術のコスト削減と手術結果の向上に役立つ。年間260万件の術後ドレナージを必要としている心臓外科、胸部外科手術分野を対象市場とする。

___

Randy Preston, Chief Business Officer

Randy Preston is Chief Business Officer of Centese Inc. He has over 15 years of experience in the medical device industry working with companies ranging from seed stage start-ups to Fortune 100. He has held key positions in business development, sales, marketing, and clinical research in both the US and EU. Randy holds a B.S. in Mechanical Engineering from California Polytechnic State University, San Luis Obispo.

Mitre Medical is a medical device company developing the Mitral Touch®, a less invasive surgical approach to provide cardiac surgeons a safer and more effective device to treat mitral valve regurgitation (MR) in patients with moderate to severe MR. These patients are the most undertreated patients in the operating room even though 70% will develop heart failure within 5 years. The present standard of care requires stopping and opening the heart. The complications and risks associated with this step limit the benefits offered by existing devices. Mitre Medical's beating heart option eliminates these risks opening a new frontier for the cardiac surgeon and their patients.

The company is based in Silicon Valley with a team experienced in medical device innovation and a track record of multiple cardiovascular medical device commercialization successes.

Mitre Medicalは、中度から重度の僧帽弁閉鎖不全／僧帽弁逆流（MR）を治療し、左室（LV）の機能改善を図ることを目的とした、安全かつ低侵襲のMitral Touch®を開発した初期段階の医療機器スタートアップ企業です。

___

John MacMahon, Chief Executive Officer

Mr. MacMahon is a serial entrepreneur specializing in early-stage product development. He has led and/or founded numerous medical device startups in the cardiovascular field.  He is an active mentor for entrepreneurs from Stanford BioDesign, Enterprise Ireland, and the Kauffman Foundation.

He is also a former COO for Maya Medical (acquired by Covidien) and was formerly with Claret Medical (Acquired by Boston Scientific) in the role of General Manager for Europe.

Mr. MacMahon received his Bachelors’ in Physics at the University of California, Santa Cruz, and a Master’s degree in Electrical Engineering at Stanford University.

MITRx is a medical device company founded by classmates from MIT Sloan School, focused on a large unmet need in heart valve disease. Our unique “micro-invasive” approach to the treatment of mitral valve disease circumvents the open-heart surgery, reducing the procedure and recovery time significantly.   Old or sick patients are often excluded from the open-heart surgery as they cannot withstand this very invasive procedure.  MITRx’s innovative device technology coupled with its optimal physiological pathway allows delivering the safest and most effective way to treat the mitral valve disease while reducing the healthcare cost.

電磁波を利用したカテーテルやガイドワイヤの位置のトラッキング・可視化技術（IOPS）とスマートセンサ搭載の手術装置を利用して、IOPSと独自の画像分析技術を活用し、患者固有の３D血管マップをリアルタイムに作成し、僧帽弁開心術に適用。これまで開心術対象外だった高齢者にも適用可能。取得特許16件、出願中38件。FDA510kは経血管大動脈修復（EVAR）で2019年6月に取得。

___

Philip Kim, CEO

Philip is a senior business leader with over 25 years of expertise in building global teams in technology companies. His deep technical experience and business acumen have made a significant impact across a wide range of companies, from startups to Fortune-500 companies. Most recently, he was VP of product marketing at Terasqure, where he was instrumental in the company's acquisition by GigOptics. He also has extensive international business experience in Asia including Japan and Korea.  Philip received B.S. and M.S. degree in Electrical Engineering from University of Maryland, and George Washington University respectively, and MBA from MIT Sloan School of Management.

___

Murali Dharhan, CMO

Dr. Dharan is an accomplished cardiothoracic surgeon and president of East Bay Cardiovascular and Thoracic Association, leading and overseeing the operation of the twenty-surgeon clinical team in addition to his own surgical schedule.  He is also the president of the Bay Area Society of Thoracic Surgeons (BAST) since 2016. He has received both surgical residency and fellowship at UCLA Medical Center and affiliated to John Muir Hospital, Stanford Valley Care Hospital, and San Ramon Regional Medical Center. Dr. Dharan also received an MBA from MIT Sloan School of Management.

PercAssist is a high-tech medical device company located in Silicon Valley California. The company was founded in 2019 and early 2020, the company started operations. We have developed, prototyped, and tested a minimally invasive approach designed for interventional cardiologists for the treatment of late-stage Congestive Heart Failure (CHF). In Japan, there are 1M people diagnosed with CHF. The minimally invasive, non-surgical, non-general anesthesia, non-anticoagulants, and outside of the blood path operation is ideal for the Japanese medical community. The rapidly aging population requires shorter treatments, shorter hospital stay, shorter recovery time, and lower cost. PercAssist technology offers all those benefits.

心拍と同期させた非血液接触型バルーンカテーテルを開発。左心室機能の強化と心筋の回復促進を目的とする。生体モデルを利用して試作、検証。

___

Gerardo V Noriega, President and CEO

As a serial entrepreneur, innovator, and scholar, I have dedicated my career to seeking fundamental improvements in the quality and development of the Medical Device Industry. As an entrepreneur and innovator, I founded four medical devices companies ReVascular Therapeutics (Acq. Boston Scientific), PROSTIS, PerfusionRx, GVMED Incubator and serve as a consultant to over 50 companies in the Silicon Valley. As a part of my mission to continue to inspire the future generations to make advancements in Biotechnology, I serve on the Board of Santa Clara University’s School of Bioengineering, as well as an Associate Professor of Bioengineering at Santa Clara University’s Bannan Graduate School of Engineering. In addition to this, I serve as a UCSF Surgical Consortium member, UCSF Catalyst Medical Innovation Program, BMES Executive Committee Founding Member, Simon Fraser School of Bioengineering Innovation Boulevard EiR.  BC, Canada. Speaker at The University of Tokyo Graduate School of Pharmaceutical Sciences, Shanghai Jiao Tong University School of Pharmacy.

In response to changing clinical needs, I assess new clinical business opportunities worldwide and develop new technologies that are responsive to the dynamic nature of the health needs of the population. My hands-on experience resides in bringing new technologies from paper to full commercialization under the “Vision and Execution” philosophy.

Our unique proximity to Silicon Valley provides a wealth of opportunities for innovation like no other place in the world. I am always on the quest for the next frontier to improve clinical therapies and reduce healthcare cost.

Radux Devices overcomes the inherent ergonomic limitations in the fluoroscopic suite with solutions that improve performance, workflow and health. Radux offers reusable and disposable systems that overcome challenges experienced during fluoroscopic surgery.  Platform one minimizes the challenges of left radial access in coronary and peripheral intervention, and other complex access. The second platform maximizes scatter radiation protection without interfering with the operators by taking advantage of location.

Radux focuses on reproducibility, simplicity, and intuitive behavior to help redirect workflow between the patient, the operator and fluoroscope; simultaneously improving patient outcomes and satisfaction, decrease hospital costs and potentially prolonging physicians’ careers.

カテーテル室や手術室での医師やスタッフの姿勢や動線を考慮し、作業効率を上げるよう設計された各種医療器具を開発。左橈骨動脈からの血管アクセスや放射線散乱波シールドなどが代表的製品。システムソリューションとしての販売を目指す。バーチャルトレーニングや社内外のリソースを活用した販売流通モデルを採用。

___

Gregory I. Gordon, MD Founder and Chief Medical Officer Radux Devices LLC

Originally from Chicago, Dr. Gordon received his bachelor’s and Medical School training at the University of Illinois; and his residency and fellowship training in diagnostic and interventional radiology at Northwestern University. With almost 25-years’ clinical experience, Dr. Gordon is currently Director of Interventional Radiology at United Vascular Omaha, NE and founder of Radux Devices.

Experiencing career threatening musculoskeletal injuries and early cataract formation, Dr. Gordon took a career turn and pursued his entrepreneurial passions. Working through UNEMed and with Nebraska Department of Economic Opportunity grants, he took his two platform ideas, StandTall and Steradian Shield, from concept to market.

Eyedaptic, is a software technology company addressing the large unmet need in the eye care field of AMD (Age Related Macular Degeneration).   Over 170 million people worldwide have AMD, is the primary cause of blindness for people over 60, and robs them of their independence.  Our visually assistive solutions are based on open market Augmented Reality (AR) glasses.  Eyedaptic’s embedded proprietary simulated natural vision software optimizes the person’s functional peripheral vision and is adaptive to the user’s vision limitation, as well as their environment and habits with machine learning, thereby giving them the Freedom to Live their Life!

機械学習を活用した視野強化ソフト。主に加齢黄斑変性症（AMD）用。オープンマーケットのARグラスに埋め込んで機能的周辺視野を最適化。視野を狭めてしまう拡大表示だけの他社製品に対して、各自の視覚障害、環境、習慣に適応できるのが特徴。

___

Jay Cormier, CEO & Founder

Jay Cormier is CEO and Founder of Eyedaptic, and an experienced technology executive and entrepreneur, with a track record of founding, growing, and turning around businesses with multiple successful exits.  Jay earned his BS in Electrical Engineering from Worcester Polytechnic Institute and an MBA from Northeastern University, and is a member of Tech Coast Angels, Orange County Chapter, as well as a mentor at the University of California, Irvine Merage Business School.

InformAI is a startup AI healthcare company that develops clinician analytics tools that speed up medical diagnosis at the point-of-care and extract data insights to improve patient outcomes.  Our products focus on high impact/ high spend medical conditions including cancer, cardiac/thoracic surgery, wound care and sinus. InformAI is currently going through FDA and CE mark approvals and is a recent recipient of a National Science Foundation contract award to build AI-enabled patient outcome predictors.  InformAI is part of the JLABS innovation center location in the Texas Medical Center, which is the world’s largest medical provider with 10 million patient encounters every year.

InformAIは、ポイントオブケアでの医療診断をスピードアップし、データの洞察を抽出して患者の転帰を改善する臨床医分析ツールを開発する新興AIヘルスケア企業です。 当社の製品は、癌、心臓/胸部外科、創傷ケア、副鼻腔などの影響が大きく、支出が多い病状に焦点を当てています。 InformAIは現在、FDAおよびCEマークの承認を受けており、AI対応の患者転帰予測因子を構築するためのNational ScienceFoundation契約賞を最近受賞しています。 InformAIは、テキサス医療センターにあるJLABSイノベーションセンターの一部です。テキサス医療センターは、毎年1,000万人の患者と出会う世界最大の医療プロバイダーです。

___

Jim Havelka, Founder and CEO

Jim Havelka is founder and CEO of InformAI. He founded the company with the belief that Al can provide a paradigm shift in using predictive analytic to assist clinicians in diagnosing medical conditions and improving patient treatment plans. Mr. Havelka has over 25 years of building, funding and leading advanced technology organizations.  Prior to starting InformAI in 2017, Mr. Havelka was a senior executive/partner at several leading global business and IT consulting organizations including KPMG, BearingPoint and Infosys. Mr. Havelka received his MBA from Rice University and BS and MS degrees in Mechanical Engineering from Texas A&M University, as well as executive education programs from Harvard Business School and Stanford Business School.

Jim Havelkaは、InformAIの創設者兼CEOです。 彼は、Alが予測分析を使用して、臨床医が医療を診断し、患者の治療計画を改善するのを支援するパラダイムシフトを提供できるという信念を持って会社を設立しました。 ハヴェルカ氏は、25年以上にわたり、高度なテクノロジー組織を構築、資金提供、および主導してきました。 2017年にInformAIを開始する前は、Havelka氏は、KPMG、BearingPoint、Infosysのいくつかの主要なグローバルビジネスおよびITコンサルティング組織の上級管理職/パートナーでした。 ハヴェルカ氏は、ライス大学でMBAを取得し、テキサスA＆M大学で機械工学の理学士号と修士号を取得し、ハーバードビジネススクールとスタンフォードビジネススクールで経営者教育プログラムを取得しました。

Oracle Health is developing a Tiny Insertable Cardiac Device to monitor and prevent Heart Failure hospitalizations, a $21B problem.

This tiny device utilizes a Multi-Sensor approach and machine learning to monitor Chronic Heart Failure. Under the skin insertion approach brings simplicity, high compliance, accuracy, and existing reimbursement that the Wearable and Heart Procedure monitors lack. Inserted device securely sends cardiac data to a smartphone, then to a cloud-based machine learning for the physician to access.

心拍、心音、肺音、活動レベルがモニタできる埋め込み可能小型装置を開発。これら包括的なデータを長期（3年）に渡って収集できる。

___

Mr. Jaeson Bang, CEO

Mr. Bang has over 15 years of expertise in clinical, technology and business operations with Medtronic and two notable Silicon Valley Med Tech startups. Mr. Bang was one of the earlier teams that helped develop Medtronic's remote monitoring device business from inception to a $700M business today, and helped develop two Class III Heart Failure devices in the US and EU. Mr. Bang has spent two years in Europe running the clinical and business operation. Mr. Bang holds Kellogg MBA.

Wound contamination is the root cause of surgical infection (SS), yet after nearly a decade of global SSI focus, hospital teams still struggle to gain control over this pervasive, invisible threat. Prescient Surgical developed and markets CleanCision, a first-in-class, advanced technology that continuously clears harmful bacteria from the incision, combining wound protection and irrigation into an intuitive and easy-to-use retraction system that has been shown to reduce SSI risk by as much as 100%.

世界各地の医療機関が10年近く、その削減に尽力しながらも苦戦している創部感染。術後合併症の根本原因の一つである創部の感染防止を目的としたCleanCisionを開発。創部の保護と洗浄を統合したシステムで術中連続的に創部の有害な細菌を除去し、その拡散を防止する。切開縫合部の感染リスクを100％削減できる症例もある。

___

Jonathan Coe, President & CEO

Before co-founding Prescient Surgical as a Stanford Biodesign Innovation Fellow, Jon held a range of roles in engineering, marketing, and leadership in the surgical instrument divisions of Johnson & Johnson and Covidien. He is an inventor on 25 issued patents and successfully launched four major products in bariatric, general, and natural orifice surgery, and surgical oncology. He also started two interventional cardiology companies, Metavention and Gradient Therapeutics, and led the IP, technical, and pre-clinical efforts at Metavention through a successful Series B investment. Jon holds SB and MS degrees in Mechanical Engineering from MIT and Georgia Tech, respectively.

Qidni Labs is aiming to serve millions of patients with kidney failure without owning any dialysis clinics. We achieve this goal through miniaturization of blood purification technology and creating wearable/portable blood purification devices with a cloud-based remote patient monitoring system that replaces the tasks performed at the dialysis clinics. We want to operate as an independent dialysis provider.

___

Dr. Morteza Ahmadi, Chief Executive Officer, Qidni Labs Inc.

Dr. Morteza Ahmadi is the founder and CEO of Qidni Labs. Morteza holds a  PhD in Biomedical Engineering and Human Factors from the University of Waterloo, Canada. He received the prestigious KRESCENT Fellowship from Kidney Foundation of Canada. During his graduate school, Morteza has also received Alexander Graham Bell Canada Graduate Scholarship from Natural Sciences and Engineering Research Council of Canada. Morteza used to be a student of Professor Donna Strickland who received Nobel Prize in Physics in 2018.

Quantason is a post-seed stage MedTech company developing a novel, ultrasound-based, radiation-free, cost-effective, reimbursable, and patient-friendly platform (IDUS™) for Preventative Breast Screening. The technology consists of a fully automated dedicated ultrasound system with two modes of operation - whole breast imaging & real-time acoustic spectroscopy - for early detection, 3D location and follow-up monitoring of a marker that its progression leads to invasive ductal carcinoma. Such early warning allows for preemptive intervention, eliminating growth of a cancerous tumor. Women worldwide, without limitations of age, breast density & size, discomfort, compliance, pregnancy, lactation, implants, or radiation therapy would foremost benefit from the new breast care paradigm. USA and global scaled hospitals, community healthcare systems (i.e., Japan & China), imaging centers/clinics, doctors' offices, and mobile units will be the other beneficiaries of the new modality, providing vital preventative care. The society will be the ultimate beneficiary of IDUS™ by saving lives, families, workforce, and cost.

The Company is seeking $10M equity capital for clinical prototyping ahead of the pilot study, followed by productization, marketing and commercialization.

乳がん（浸潤性乳管癌）の早期発見・予防、進行追跡を目的とした完全自動型超音波診断技術を開発。初めは、40歳未満や十分な検診が受けられていない40歳以上で、特に乳房密度の高い女性を対象にしている。放射線、年齢、乳房密度と大きさ、妊娠／授乳中、インプラント、放射線治療中と言ったX線マンモグラフィに関わる制約を排除することができる。検査は10分ほどしかかからず、完全デジタル化されており、コスト効率の良さや操作性、患者への負担が少ないなどが利点である。

___

Dr. Edmond Rambod, Chairman & CEO

Dr. Edmond Rambod is a serial entrepreneur, an executive, a Doctor of Medicine and an inventor, with 25 years of experience focusing on tech-innovations applications in medicine. Under his leadership, Quantason has pioneered and perfected the principal implementation of IDUS™ in preventative breast screening. He fellowshipped in Cardiac Surgery at UCLA and Cedars-Sinai, was a senior scientist at Caltech, an advisor to major MedTech companies and CSO at NASDAQ:NQCI, where he invented the extracorporeal renal and cardiac technologies, sold to Fresenius.

Strengths: Trans-disciplinary knowledge, management skills, results-driven, systematic approach

Education: Engineering and Medicine (Technion, Israel); EMBA (UCLA).

Awarded/Pending Patents: 50.

Regentys is an early stage medical device company creating a first in class, non-surgical, non-drug treatment option for patients with ulcerative colitis and other gastrointestinal diseases. Our technology has already been successfully commercialized in multiple other medical applications. We offer a novel application of a proven technology to a billion-dollar market in need of alternative treatments.

潰瘍性大腸炎他の消化器疾患に対し、手術や薬物以外の治療選択肢を提供する。この技術は既に他の治療用途で商用化されており実績がある。代替治療を必要とする市場は10億ドル規模。

___

Marc Ramer (Founder / Advisor)

23-year career as a biomedical engineer in the medical device industry, with a primary focus on R&D. Has participated in or led multiple product development programs including stents, a microguidewire, embolic coil, coated vascular graft, synthetic aortic heart valve, orthopedic implants and two laparoscopic surgical devices. Has initiated significant clinical trials for novel medical devices around the world.

Principal R&D Engineer at Cordis (a Johnson & Johnson company). Director of R&D Innovia LLC, an early-stage medical device company.

BSE and MS in Materials Science and Engineering (Biomaterials specialty) from the University of Florida. Eight US patents and others pending.

___

Rick Bulman (CEO)

Director and founder of Regentys, and has served as Executive Vice President of Legal and Business Affairs of the Company since 2013.  More than 25 years of business and legal experience with emerging life sciences, technology companies and major law firms. Previously general counsel to Brickell Biotech, Inc., a Boulder, CO dermatology drug development company, Concordia Pharmaceuticals, Inc., a Miami, FL anti-cancer drug development company, and IVAX Corporation, a global pharmaceutical developer.

JD State University of New York at Buffalo, Faculty of Law and Jurisprudence, BA in Public Affairs from the State University of New York at Albany.

The Slate Therapeutics team has invented and developed the novel Effervescent Foam System, delivering therapeutics to the oral-nasal pharynx addressing chronic rhinosinusitis patient pain points. It is an easily administered, non-surgical treatment that can replace drug eluting stents and drug coated balloons. Slate’s founding team has been working together for over 15 years, with extensive experience founding and growing MedTech businesses. Together they have 150 patents and patent applications and their products have generated sales in excess of $800M worldwide. Over the past 10 years, the founders have completed 5 transactions to large multinational companies. The technology behind Slate Therapeutics addresses a clear, unmet clinical need and has the ability to positively affect lives from the US to Japan and everywhere in between. Slate is currently raising a $5M Series A to support regulatory submission, a pivotal clinical study and eventual commercialization of the stent replacement system.

泡状薬剤を患部に送達し持続的な薬物治療の実現を目指す。慢性副鼻腔炎の術後に使われる薬剤投与用ステントに代わる非侵襲的な治療方法を提供する。また布製マスクの代わりに殺菌フォームを使ったCOVID-19薬用マスクや脳への薬剤デリバリーへの適用も検討されている。

___

Gary Binyamin, PhD – CEO

Dr. Binyamin has over 20 years of experience bringing technologies from concept to commercialization in medical device, diagnostic, pharmaceutical and material science companies. As Chief Technology Officer for TriReme Medical LLC, Dr. Binyamin developed novel combination products. Prior to that he led the founding of a cutaneous wound healing venture, invented a pharmaceutical discovery platform and development microfluidic devices. He has contributed to the generation of green technologies and consumer products. Dr. Binyamin received a BS from the University of Illinois at Urbana-Champaign and a PhD from the University of Texas at Austin. Post-graduate studies were completed at Stanford University.

Smartlens is a clinical-stage company with a vision of preventing blindness due to Glaucoma. Smartlens has developed a non-invasive, electronics-free, ultra-sensitive, soft contact lens capable of monitoring intraocular pressure, the primary risk factor of Glaucoma.

Smartlens’ intuitive technology helps improve the understanding of disease progression, efficacy of treatments and better decisions about managing the disease. Our platform provides seamless telehealth and remote patient monitoring capabilities and helps improve clinical workflow reducing treatment costs.

Our intuitive technologies enable measurements of IOP anywhere any time, which are shared with the medical provider as actionable insights through their easy-to-use and customized dashboard.

非侵襲的で、電子機器を使わず、正確で、使いやすく、低価格で眼圧（IOP）を測定できるソフトコンタクトレンズを開発。主に緑内障向け。これまでは3～6ヶ月に一度の診察時にしか測定できなかった眼圧をいつでもどこでもモニタすることができる。既に前臨床試験を終了しており、3件の試験をNature Medicineを含む査読学会誌で発表。国内外で10件の特許を申請、4件は既に取得済。

___

Savas Komban, CEO & Co-Founder

Savas Komban is the CEO and Cofounder of Smartlens. He is an industrial engineer by training and a serial entrepreneur for 2 decades. Earlier in his career, Savas founded itelligence TR, and rapidly grew the business to the global scale, that led the way for its acquisition by NTT. He continued as Founder & CEO and Head of Global Business Innovation for NTTD, where he led its transformation to a large-scale global corporation and grew the business 5 times in 4 years. He is serving as the Chairman of the Board at Silicon Valley Ignite and Partner at Mighty Capital.